

NMSGROUP

ONCOLOGY FORWARD

**NERVIANO
MEDICAL
SCIENCES**

ACCELERERA

NERPHARMA

SIMIS

NMS Group S.p.A. Announces Resignation of Angelo Colombo as CEO of Accelerera Srl and NerPharMa Srl; Hugues Dolgos – CEO of NMS Group S.p.A. – Appointed Interim CEO

Nerviano, 5 May 2022 — NMS Group SpA today announced that its CEO, Hugues Dolgos, has accepted the resignation of Angelo Colombo as CEO of Accelerera Srl and NerPharMa Srl, effective 31 May 2022. Hugues Dolgos will act as interim CEO for both companies. A search for a permanent CEO will begin shortly.

“I look forward to working even closely with our colleagues from Accelerera and NerPharMa to complete our on-going transformation plan together and achieve our strategic goals, to create more values to our Board and clients and eventually benefit patients globally,” said Dr. Dolgos.

Mr. David Wong, Chairman of NMS Group SpA stated, “The Board is excited to have Hugues expand his responsibilities building on his amazing progress in the past few months. We are sure that Hugues will lead the group with his integral knowledge of all aspects of the business and his strong relationships throughout the industry to bring more opportunities to the companies. I wish him all the best in his future endeavors and thank him on behalf of the entire Board.”

Mr. Colombo stated, “I want to thank everyone that worked side by side with me and made Accelerera and NerPharMa two leading CRO and CDMO today. It has been a great honor to work with our investors, Board and brilliant team over the past 5 years. I realize that all journeys must ultimately come to an end and want to wish Hugues and the entire team success as they continue to grow the business.”

###

About NMS Group

[NMS Group](#) is the largest oncological R&D company in Italy. With more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently Entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.

The NMS Group has three subsidiaries. NMS Srl is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen of anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelerera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug product supporting clinical developments and commercialization.

Hugues Dolgos

Hugues Dolgos is a seasoned biopharma leader with over 20 years of experience across the R&D value chain from new concept to post approval in multiple therapeutic areas and a proven track record in oncology and immuno-oncology. Dr. Dolgos joins from Servier where he was Global Head of Oncology and a member of the R&D leadership team. Prior to that, he held notable positions at Merck KGaA as Vice President and

NMSGROUP

ONCOLOGY FORWARD

**NERVIANO
MEDICAL
SCIENCES**

ACCELERERA

NERPHARMA

SIMIS

Head of R&D Strategy PMO, Quantitative Pharmacology and Drug Disposition, setting up strategic directions to best select and ultimately deliver candidate drugs even beyond approval. During the past decades, he has been leading large teams at international top-tier companies like AstraZeneca and Merck KGaA on R&D strategy, R&D governance and capabilities building including Modeling & Simulation, DMPK, Clinical Pharmacology, Bioinformatics, R&D digital, forming alliance, driving changes and creating values for the organizations. He holds a Pharm D. from the University of Pharmacy, Paris V and Master from the university of Paris V and University of Pierre et Marie Curie (Paris VI).

Media contact: Sidney Dung Sidney.dung@nmsgroup.it